New hope for muscle stiffness: Once-Daily pill tested in myotonic dystrophy
NCT ID NCT06523400
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial tests whether a once-daily dose of mexiletine PR can safely reduce muscle stiffness (myotonia) in people with myotonic dystrophy types 1 and 2. About 176 participants will receive either the drug or a placebo for 26 weeks. The main measure is how quickly hand muscles relax after a strong squeeze.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mexiletine PR (prolonged-release granules for oral suspension)
- What this could lead to
- If successful, this could provide a once-daily treatment option to reduce muscle stiffness and improve daily function for people with myotonic dystrophy.
- What could go wrong
- This is a Phase 3 trial, but it's still testing a drug that may not work better than placebo. Side effects are possible, and the benefit may be modest or not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital
RECRUITINGAarhus, Denmark
-
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
RECRUITINGRome, Italy
-
Laboratory for Muscle Diseases and Neuropathies
RECRUITINGLeuven, Belgium
-
Ludug-Maximilians University
RECRUITINGMünchen, Germany
-
Saint George's University Hospitals NHS Foundation Trust
RECRUITINGLondon, United Kingdom
-
University College Hospital
RECRUITINGLondon, United Kingdom
-
University Hospital of Madrid
RECRUITINGMadrid, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we measure the progression of childhood myotonic dystrophy well enough to test new therapies?
- Scientists hunt for biomarkers to unlock DM1 treatments
- Could virtual reality help kids with a rare muscle disease read emotions better?
- New study tracks Long-Term safety of muscle stiffness drug namuscla
- No travel needed: new study uses video calls to uncover genetic secrets of childhood muscle disease
- Brain scans reveal diabetes link to cognitive decline in rare disease